Drugs / SLC-391
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT05278845 | Feb → Jun 2022 | — | SignalChem Lifesciences Corporation | Completed | No outcome recorded |
| Phase 1 | NCT03990454 | Sep 2019 → Jun 2023 | cancer | SignalChem Lifesciences Corporation | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05860296 | May 2023 → Dec 2025 | non-small cell lung carcinoma | SignalChem Lifesciences Corporation | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLC-391 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05278845 ↗ |
| Known as | SLC-0211 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095196 ↗ |
| Action | Inhibit | “SLC-391 is an AXL inhibitor” NCT03990454 ↗ |
| Modality | Small molecule | “SLC-391 is a novel, potent and specific small molecule inhibitor of receptor tyrosine kinase AXL” NCT05860296 ↗ |
| Route | Oral | “SLC-391 administered orally” NCT03990454 ↗ |
| Target | AXL | “SLC-391 is an AXL inhibitor” NCT03990454 ↗ |